Keene & Associates, Inc. Bristol Myers Squibb CO Transaction History
Keene & Associates, Inc.
- $121 Million
- Q2 2024
A detailed history of Keene & Associates, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Keene & Associates, Inc. holds 60,313 shares of BMY stock, worth $2.94 Million. This represents 2.07% of its overall portfolio holdings.
Number of Shares
60,313
Previous 59,064
2.11%
Holding current value
$2.94 Million
Previous $3.2 Million
21.82%
% of portfolio
2.07%
Previous 2.41%
Shares
11 transactions
Others Institutions Holding BMY
# of Institutions
2,399Shares Held
1.5BCall Options Held
29.7MPut Options Held
32.2M-
Vanguard Group Inc Valley Forge, PA187MShares$9.09 Billion0.15% of portfolio
-
Black Rock Inc. New York, NY159MShares$7.73 Billion0.15% of portfolio
-
State Street Corp Boston, MA91.4MShares$4.45 Billion0.17% of portfolio
-
Jpmorgan Chase & CO New York, NY74.6MShares$3.63 Billion0.27% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA59.1MShares$2.88 Billion0.47% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $104B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...